Eli Lilly beats Q3 2026 earnings, lifts full‑year revenue outlook to $91‑$92 B

Eli Lilly reported third‑quarter 2026 revenue of $24.4 billion, up 39% year‑over‑year, and earnings of $7.22 per share on a GAAP basis and $7.48 on a non‑GAAP basis. The company raised its full‑year 2026 revenue guidance to $91 billion‑$92 billion while trimming its adjusted EPS outlook to $35‑$36 per share because of $4.57 per share of acquisition‑related charges. Strong sales of Mounjaro ($10.72 billion) and Zepbound ($5.35 billion) drove the results, while the new obesity pill Foundayo generated $184 million.

The higher revenue forecast signals continued growth from the GLP‑1 franchise, which may support a bullish outlook for the stock. The lower EPS guidance reflects one‑time acquisition charges, reducing near‑term profit expectations despite the earnings beat.

  • 1Q3 2026 revenue was $24.4 billion, a 39% increase versus Q3 2025.
  • 2GAAP EPS for Q3 2026 was $7.22 per share; non‑GAAP EPS was $7.48 per share.
  • 3Full‑year 2026 revenue guidance was raised to $91 billion‑$92 billion.
  • 4Adjusted EPS guidance for 2026 was trimmed to $35.00‑$36.00 per share.
  • 5Acquisition‑related charges added $4.57 per share, offsetting a $4.07 improvement in underlying profit guidance.
  • 6Mounjaro sales in Q3 were $10.72 billion; Zepbound sales were $5.35 billion.

Sources